Lentiviral Minigene Vaccine Uses, Dosage, Side Effects and more

LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).

As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

Attribute	Details
Trade Name	Lentiviral Minigene Vaccine
Generic	LV-SMENP Vaccine
LV-SMENP Vaccine Other Names	Covid-19 Synthetic Minigene Vaccine, Lentiviral Minigene Vaccine, LV-SMENP
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	January 7, 2025 at 1:49 am

Innovators Monograph